Compare MSBIP & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MSBIP | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 861 | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2011 | 2024 |
| Metric | MSBIP | YDESW |
|---|---|---|
| Price | $25.18 | $0.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 8.2K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $0.19 |
| 52 Week High | $27.07 | $1.80 |
| Indicator | MSBIP | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 49.21 |
| Support Level | $24.35 | $0.35 |
| Resistance Level | $25.49 | $0.58 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 15.94 | 41.07 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.